N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease.

Xiong WangJiazhao XieLu TanYanjun LuNa ShenJiaoyuan LiHui HuHuijun LiXiaoguang LiLiming Cheng

Published in: Translational neurodegeneration (2023)

In conclusion, our study demonstrated that m6A-modified circRIMS2 mediates the synaptic and memory impairments in AD by activating the UBE2K-dependent ubiquitination and degradation of GluN2B via sponging miR-3968, providing novel therapeutic strategies for AD.

Keyphrases

signaling pathway
working memory
cell proliferation
prefrontal cortex
mild cognitive impairment